RS53790B1 - Farmaceutske kompozicije koje sadrže n-(4-(2-amino-3-hloropiridin-4-iloksi)-3-fluorofenil-l-(4-fluorofenil)-2-okso-1,2-dihidropiridin-3-karboksamid - Google Patents
Farmaceutske kompozicije koje sadrže n-(4-(2-amino-3-hloropiridin-4-iloksi)-3-fluorofenil-l-(4-fluorofenil)-2-okso-1,2-dihidropiridin-3-karboksamidInfo
- Publication number
- RS53790B1 RS53790B1 RS20150055A RSP20150055A RS53790B1 RS 53790 B1 RS53790 B1 RS 53790B1 RS 20150055 A RS20150055 A RS 20150055A RS P20150055 A RSP20150055 A RS P20150055A RS 53790 B1 RS53790 B1 RS 53790B1
- Authority
- RS
- Serbia
- Prior art keywords
- compound
- cancer
- pxrd
- spectrum
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32971010P | 2010-04-30 | 2010-04-30 | |
| PCT/US2011/034417 WO2011137274A1 (en) | 2010-04-30 | 2011-04-29 | Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS53790B1 true RS53790B1 (sr) | 2015-06-30 |
Family
ID=44209564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20150055A RS53790B1 (sr) | 2010-04-30 | 2011-04-29 | Farmaceutske kompozicije koje sadrže n-(4-(2-amino-3-hloropiridin-4-iloksi)-3-fluorofenil-l-(4-fluorofenil)-2-okso-1,2-dihidropiridin-3-karboksamid |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8911785B2 (https=) |
| EP (1) | EP2563763B1 (https=) |
| JP (1) | JP5820874B2 (https=) |
| KR (1) | KR101897302B1 (https=) |
| CN (1) | CN102971296B (https=) |
| DK (1) | DK2563763T3 (https=) |
| ES (1) | ES2533075T3 (https=) |
| HR (1) | HRP20150105T1 (https=) |
| MY (1) | MY183769A (https=) |
| PH (1) | PH12012502019A1 (https=) |
| PL (1) | PL2563763T3 (https=) |
| PT (1) | PT2563763E (https=) |
| RS (1) | RS53790B1 (https=) |
| SG (1) | SG184891A1 (https=) |
| SI (1) | SI2563763T1 (https=) |
| SM (1) | SMT201500069B (https=) |
| WO (1) | WO2011137274A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104080905B (zh) * | 2011-12-22 | 2016-11-16 | 生命技术公司 | 细胞培养基和方法 |
| KR101545268B1 (ko) | 2015-02-05 | 2015-08-20 | 보령제약 주식회사 | 정제 및 이의 제조방법 |
| WO2016126012A1 (en) * | 2015-02-05 | 2016-08-11 | Boryung Pharmaceutical Co., Ltd | Tablet and method of preparing the same |
| WO2020150307A1 (en) * | 2019-01-15 | 2020-07-23 | The Translational Genomics Research Institute | Phosphonate conjugates and uses thereof |
| US20230257364A1 (en) * | 2022-02-16 | 2023-08-17 | Cmg Pharmaceutical Co., Ltd. | Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| ID21762A (id) * | 1996-09-24 | 1999-07-22 | Lilly Co Eli | Formulasi partikel bersaput |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| WO2006118210A1 (ja) * | 2005-04-28 | 2006-11-09 | Eisai R & D Management Co., Ltd. | ジヒドロピリジン系化合物の分解を防止する方法 |
| TR200504775A1 (tr) | 2005-11-30 | 2007-10-22 | Esen Beki̇r | Kendinden metal takviyeli pvc pencere ve kapı profilleri |
| PT1808164E (pt) * | 2006-01-05 | 2009-03-17 | Teva Pharma | Método de granulação húmida para a preparação de composições farmacêuticas de aripiprazole |
| US7851489B2 (en) * | 2006-11-08 | 2010-12-14 | Bristol-Myers Squibb Company | Pyridinone compounds |
| US20080260837A1 (en) * | 2007-04-20 | 2008-10-23 | Qpharma, L.L.C. | Physically stable aqueous suspensions of active pharmaceuticals |
| US8263652B2 (en) * | 2007-10-31 | 2012-09-11 | Sk Biopharmaceuticals Co., Ltd. | Stabilized pediatric suspension of carisbamate |
| JP5693239B2 (ja) | 2008-01-23 | 2015-04-01 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ４−ピリジノン化合物および癌についてのその使用 |
-
2011
- 2011-04-29 CN CN201180032341.1A patent/CN102971296B/zh active Active
- 2011-04-29 RS RS20150055A patent/RS53790B1/sr unknown
- 2011-04-29 PH PH1/2012/502019A patent/PH12012502019A1/en unknown
- 2011-04-29 EP EP11717917.6A patent/EP2563763B1/en active Active
- 2011-04-29 WO PCT/US2011/034417 patent/WO2011137274A1/en not_active Ceased
- 2011-04-29 KR KR1020127031220A patent/KR101897302B1/ko active Active
- 2011-04-29 DK DK11717917.6T patent/DK2563763T3/en active
- 2011-04-29 JP JP2013508267A patent/JP5820874B2/ja active Active
- 2011-04-29 PT PT11717917T patent/PT2563763E/pt unknown
- 2011-04-29 ES ES11717917.6T patent/ES2533075T3/es active Active
- 2011-04-29 HR HRP20150105AT patent/HRP20150105T1/hr unknown
- 2011-04-29 MY MYPI2012004708A patent/MY183769A/en unknown
- 2011-04-29 PL PL11717917T patent/PL2563763T3/pl unknown
- 2011-04-29 SI SI201130405T patent/SI2563763T1/sl unknown
- 2011-04-29 US US13/643,561 patent/US8911785B2/en active Active
- 2011-04-29 SG SG2012076865A patent/SG184891A1/en unknown
-
2014
- 2014-09-15 US US14/486,139 patent/US9233948B2/en active Active
-
2015
- 2015-03-18 SM SM201500069T patent/SMT201500069B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2533075T3 (es) | 2015-04-07 |
| US20150065719A1 (en) | 2015-03-05 |
| SG184891A1 (en) | 2012-11-29 |
| US8911785B2 (en) | 2014-12-16 |
| KR20130100237A (ko) | 2013-09-10 |
| US20130039989A1 (en) | 2013-02-14 |
| EP2563763A1 (en) | 2013-03-06 |
| PH12012502019A1 (en) | 2017-08-18 |
| WO2011137274A1 (en) | 2011-11-03 |
| DK2563763T3 (en) | 2015-04-07 |
| HK1179260A1 (en) | 2013-09-27 |
| KR101897302B1 (ko) | 2018-09-11 |
| PT2563763E (pt) | 2015-03-31 |
| SI2563763T1 (sl) | 2015-03-31 |
| JP5820874B2 (ja) | 2015-11-24 |
| EP2563763B1 (en) | 2014-12-31 |
| SMT201500069B (it) | 2015-05-05 |
| HRP20150105T1 (hr) | 2015-03-13 |
| CN102971296A (zh) | 2013-03-13 |
| JP2013525455A (ja) | 2013-06-20 |
| AU2011245269A1 (en) | 2012-12-20 |
| PL2563763T3 (pl) | 2015-06-30 |
| US9233948B2 (en) | 2016-01-12 |
| MY183769A (en) | 2021-03-12 |
| CN102971296B (zh) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4563150A2 (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer | |
| US20220194946A1 (en) | Fgfr inhibitors and methods of making and using the same | |
| CA3153752A1 (en) | Solid state crystalline forms of a selective potassium channel modulator | |
| US9233948B2 (en) | Pharmaceutical compositions comprising N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide | |
| CN110291079A (zh) | 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法 | |
| EP2819998B1 (en) | Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1h-indazol-5-yloxy)benzyl)urea hydrochloride | |
| US9453011B2 (en) | Crystal form of dabrafenib mesylate and preparation method thereof | |
| JP6463874B2 (ja) | 医学的適用用の３−（１，２，４−トリアゾロ［４，３−ａ］ピリジン−３−イルエチニル）−４−メチル−Ｎ−（４−（（４−メチルピペラジン−１−イル）メチル）−３−トリフルオロメチルフェニル）ベンズアミドの新規な結晶性塩形態 | |
| AU2011245269B2 (en) | Pharmaceutical compositions comprising N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide | |
| WO2008157291A2 (en) | CRYSTALLINE FORMS OF (3Aα, 4β, 5α, 7β, 7Aα)-4-(OCTAHYDRO-5-ETHYLSULFONAMIDO-4,7-DIMETHYL-1,3-DIOXO-4,7-EPOXY-2H-ISOINDOL-2-YL)-2-(TRIFLUOROMETHYL)BENZONITRILE AND METHOD OF PREPARATION | |
| HK1179260B (en) | Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide | |
| JP2025521226A (ja) | ５－（２－（４－（４－フルオロ－２－メチル－１ｈ－インドール－５－イルオキシ）－６－メトキシキノリン－７－イルオキシ）エチル）－５－アザスピロ［２．４］－ヘプタン－７－オール結晶、リン酸塩及びそのエナンチオマーの生物学的活性 | |
| HK40123031A (zh) | 晶体、药物组合物及其制备方法和应用 | |
| WO2025147497A1 (en) | Solid forms comprising (5r,6s)-10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1h-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane] 2,2-dioxide, and compositions comprising and methods of using the same | |
| HK40079891A (en) | Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists | |
| HK40079890A (en) | Compositions and methods related to picolinylpiperidine 5-ht1f agonists | |
| HK1254731B (zh) | 用於医学应用的一种1，2，4-三唑并[4，3-a]吡啶的衍生物的新型结晶盐形式 |